Use of cholinesterase inhibitors in dementia

@inproceedings{Holden2002UseOC,
  title={Use of cholinesterase inhibitors in dementia},
  author={Mark Holden and Cornelius Kelly},
  year={2002}
}
Alzheimer’s disease is the most common cause of dementia in older people, with about half a million people affected in the UK. Its effects are devastating and far-reaching for sufferers, their carers and society in general – the Audit Commission estimated the annual cost of dementia care for 1998–1999 at £6.1 billion (Audit Commission, 2000). There is no cure and it is terminal within 3 to 7 years of diagnosis. Given an estimated doubling of dementia cases over the next 50 years (Melzer et al… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Guidance on the use of donepezil , rivastigmine and galantamine for the treatment of Alzheimer ’ s disease

  • E. K. Perry, B. E. Tomlinson, G. Blessed
  • 2001

A randomised trial evaluating the efficacy and safety of rivastigmine in patients with mild to moderately severe Alzheimer ’s disease

  • J. Corey-Bloom, R. Anand, J. Veitch
  • International Journal of Geriatric…
  • 1998
1 Excerpt

Similar Papers

Loading similar papers…